Circulating Endothelial Progenitor Cells and Aortic Aneurysm (ANOPEC3)

H

Hopital Jean Minjoz

Status

Unknown

Conditions

- Aortic Aneurysm

Study type

Observational

Funder types

Other

Identifiers

NCT01918982
147/362

Details and patient eligibility

About

We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Full description

Circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- have been shown to be inversely correlated to aortic aneurysm size. We aimed to see if aortic aneurysms could be followed-up by circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level. 40 patients followed for known aortic aneurysm >30mm and <50mm will be followed up every 6 months during 2 years. Each 6 months they will have a consultation by their physiologist with an echo or a CT-scan. At the same time, a 10ML blood sample will be taken to assess the circulating endothelial progenitor cells CD34+144+CD14- and CD34+VEGF-R2+CD14- blood level.

Enrollment

40 estimated patients

Sex

All

Ages

18 to 85 years old

Volunteers

No Healthy Volunteers

Inclusion criteria

Aortic aneurysm size >30mm and > 50mm

Exclusion criteria

  • Infectious disease
  • Inflammatory disease
  • Liver insuffisency
  • Cancer evolutive
  • Pregnant women

Trial design

40 participants in 1 patient group

Aortic aneurysm
Description:
Patients with aortic aneurysm >30mm and < 50mm

Trial contacts and locations

0

Loading...

Central trial contact

Sidney Chocron

Data sourced from clinicaltrials.gov

Clinical trials

Find clinical trialsTrials by location
© Copyright 2024 Veeva Systems